Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

In the dose-ranging study, the changes from baseline did not reach statistical significance compared with placebo (except for the change in 4 hours postprandial glucose with vildagliptin 50 mg once daily), but the numerical values were broadly consistent with a dose-related effect reaching a plateau at 50 or 100 mg/day ( Ristic et al. 2005 ; Table 4 ).

also in 111,027 other papers